人民财讯12月12日电，汇宇制药(688553)12月12日公告，公司于近日收到国家药品监督管理局核准签发 的公司产品盐酸尼卡地平注射液的药品注册证书。盐酸尼卡地平注射液临床上用于手术时异常高血压的 紧急处理和高血压急症。 ...

证券代码：688553 证券简称：汇宇制药 公告编号：2025-093 四川汇宇制药股份有限公司 持股5%以上股东股份被轮候冻结的公告 登录新浪财经APP 搜索【信披】查看更多考评等级 二、截至2025年12月10日，股东黄乾益所持公司股份累计被司法冻结、轮候冻结情况如下： ■ 三、公司股东所持股份被司法冻结/轮候冻结对公司的影响及风险 提示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 截至公告披露日，四川汇宇制药股份有限公司（以下简称"公司"）股东黄乾益先生直接持有公司股份 27,219,439股，占公司总股本比例为6.43%。 ● 近日，股东黄乾益先生所持公司股份被四川省安岳县人民法院轮候冻结1,300,000股。截至2025年12月 10日，股东黄乾益先生所持公司股份累计被轮候冻结股份数7,650,738股，占其所持公司股份比例为 28.11%，占公司总股本比例为1.81%。 近日，公司股东黄乾益先生通知公司其所持公司部分股份于近期被四川省安岳县人民法院轮候冻结，具 体情况如下： 一、本次股份 ...

证券代码：688553 证券简称：汇宇制药 公告编号：2025-093 四川汇宇制药股份有限公司 持股 5%以上股东股份被轮候冻结的公告 近日，公司股东黄乾益先生通知公司其所持公司部分股份于近期被四川省安 岳县人民法院轮候冻结，具体情况如下： | 股东 | 是 | 否 | 为控 | 本 次 | 冻结 | 占 其 | 所 | 持 | 占公司 | 是否为 | 本 次 | 轮 | 本 | 次 | 冻 | 本 次 | 冻 | 结 | 冻结原因 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 股 | 股 | 东及 | 股 份 | 数量 | 股份比例 | | | 总股本 | 限售股 | 候 冻 | 结 | 结 | 到 | 期 | 申请人 | | | | | | | 一 | 致 | 行动 | （股） | | | | | 比例 | | 起始日 | | 日 | | | | | | | | | | 人 ...

每经AI快讯，汇宇制药（SH 688553，收盘价：18.65元）12月11日晚间发布公告称，近日，股东黄乾益 先生所持公司股份被四川省安岳县人民法院轮候冻结1,300,000股。截至2025年12月10日，股东黄乾益先 生所持公司股份累计被轮候冻结股份数7,650,738股，占其所持公司股份比例为28.11%，占公司总股本 比例为1.81%。 每经头条（nbdtoutiao）——白金信用卡权益大缩水：贵宾厅限次、酒店减量⋯⋯银行吐槽没赚头，"羊 毛党"薅了个寂寞 2024年1至12月份，汇宇制药的营业收入构成为：医药占比99.18%，其他业务占比0.82%。 截至发稿，汇宇制药市值为79亿元。 （记者 曾健辉） ...

汇宇制药公告称，股东黄乾益直接持有公司股份27,219,439股，占总股本6.43%。近日，其1,300,000股 被四川省安岳县人民法院轮候冻结，原因是债务合同纠纷保全。截至2025年12月10日，累计被轮候冻结 股份数7,650,738股，占其所持股份28.11%，占公司总股本1.81%。黄乾益非控股股东或第一大股东及其 一致行动人，该事项不影响公司控制权和生产经营。 ...

Core Viewpoint - The company will decide on potential share reductions based on development needs and the stock price fluctuations of Tongyuan Kang [1] Summary by Relevant Sections - Company Holdings: The company holds shares in Tongyuan Kang and will provide updates on its holdings in regular reports [1]

Investment Rating - The report does not explicitly state an investment rating for the industry [2] Core Views - The pharmaceutical and biotechnology sector saw a weekly increase of 2.67%, underperforming the Wind All A index (2.9%) but outperforming the CSI 300 index (1.64%). The raw material drug sector experienced a decline of 4.27%, while chemical preparations and pharmaceutical circulation products increased by 4.18% and 3.71%, respectively [3][8] - Recent policies in Shanghai and Beijing aim to support the high-quality development of the medical device industry, indicating a shift towards innovation and global competitiveness in this sector. The report suggests monitoring the transformation progress of leading companies in the medical device field [3][12] - Flu activity is on the rise, with the percentage of flu-like cases reported by sentinel hospitals in southern provinces reaching 7.8%, up from 6.8% the previous week, and higher than the same period in 2022 and 2024 [3][11] Summary by Sections Market Weekly Review - The pharmaceutical and biotechnology sector increased by 2.67% from November 24 to November 28, 2025, with raw material drugs declining by 4.27% and chemical preparations increasing by 4.18% [8][9] - Individual stock performances included significant gains for Haiwang Biological (38.2%), Yue Wannianqing (36.2%), and Guangji Pharmaceutical (31.7%), while *ST Changyao (-15.3%), Huitai Medical (-9.6%), and Kangwei Century (-8.8%) saw notable declines [11] Industry News and Key Company Announcements Important Industry Events - The report highlights the increase in flu-like illness percentages in both southern (7.8%) and northern (8.6%) provinces, indicating a significant rise in flu activity compared to previous years [11][12] Industry News - Significant approvals were noted, including the NMPA's approval of Xinmeiyue® for treating moderate to severe plaque psoriasis and the FDA's accelerated approval of Sibeprenlimab for IgAN treatment [12][14] Company Announcements - Notable announcements include the FDA approval of a generic injectable drug by Jianyou Co. and the successful completion of a Phase III trial for JS001sc, a subcutaneous PD-1 monoclonal antibody for non-small cell lung cancer [15][16]

Policy Developments - The State Council, led by Li Qiang, held a meeting to advance the provincial coordination of basic medical insurance [2] Medical Device Approvals - Yuhanglong received two medical device registration certificates for diagnostic kits related to primary biliary cholangitis and idiopathic membranous nephropathy, enhancing its product line in liver and kidney disease diagnostics [4] - Hengrui Medicine announced the approval of clinical trial notifications for five drugs, including the humanized anti-PD-L1 monoclonal antibody Abedilizumab, with total R&D investments amounting to approximately 1.1 billion yuan [5] Capital Market Activities - Mindray Medical's chairman, Li Xiting, plans to increase his stake in the company by 200 million yuan, having already purchased shares worth approximately 30 million yuan [7] - Huayu Pharmaceutical intends to establish a private equity fund focused on the biomedical sector, with an initial commitment of 150 million yuan from the company [8][9] Industry Milestones - The first brain-computer interface surgery in China was successfully completed, utilizing a device from Wuhan Zhonghua Brain-Machine Fusion Technology Co., with the procedure priced according to government regulations [11] Clinical Trials and Collaborations - Buchang Pharmaceutical's subsidiary signed a contract for clinical trials of a new product, with a total cost of approximately 60 million yuan, aimed at enhancing the company's drug development capabilities [12] - Jincheng Pharmaceutical terminated negotiations with Giskit Pharma B.V. regarding exclusive commercialization rights, with no financial impact expected [14]

Group 1 - Tianpu Co., Ltd. has experienced significant stock price volatility, with a cumulative increase of 451.80% from August 22, 2025, to November 27, 2025, leading to a suspension of trading for verification starting November 28, 2025 [1] Group 2 - FAW Jiefang plans to increase capital in its joint venture, Jiefang Times, by 191 million yuan, with a total capital increase of 412 million yuan alongside CATL and new investor Telepower, enhancing competitiveness in the new energy commercial vehicle sector [2] Group 3 - Qingdao Beer plans to invest in low-risk financial products with a maximum daily balance of 10 billion yuan over the next 12 months to improve fund efficiency and returns for shareholders [3] - Haohan Deep plans to acquire a 16.0656% stake in Guorui Smart for 70.68864 million yuan, increasing its ownership to 51.0656% [3] Group 4 - Huazhi Jie intends to invest 100 million yuan to establish Suzhou Kangyang Robot Co., Ltd., aligning with its strategic development plans [4] - Maide Medical's chairman proposes a share buyback of 20 million to 40 million yuan to reduce registered capital [4] Group 5 - Haichang New Materials plans to acquire 51% of Shenzhen Xinwei Communication Technology Co., Ltd. for 23.46 million yuan, gaining control over the company [5] - Hunan Gold's subsidiary obtained a mining license for a tungsten mine with an annual production capacity of 990,000 tons [5] Group 6 - Tianli Lithium Energy received two invention patents related to lithium-ion battery electrode materials, enhancing its core technology and competitive edge [6] Group 7 - Changan Automobile's indirect controlling shareholder underwent a restructuring, resulting in a new entity, China Changan Automobile Group, which holds 35.04% of Changan Automobile's shares [7] Group 8 - *ST Lian Shi's stock will resume trading on November 28, 2025, following a capital reserve increase [8] - Jia You International signed a strategic cooperation memorandum with the China-Africa Development Fund, expected to positively impact business development [8] Group 9 - China Aluminum International's subsidiary won a contract for a project worth 2.9086858 billion yuan, which could enhance the company's operational scale and profitability [9] Group 10 - Guizhou Sanli changed its stock abbreviation to "Sanli Pharmaceutical," while maintaining its full name and stock code [10] - China CRRC plans to spin off its subsidiary, CRRC Qichu, for listing on the Shenzhen Stock Exchange, retaining control over the subsidiary [10] Group 11 - Haowei Group's subsidiary plans to invest 200 million yuan in a private equity fund focused on integrated circuit-related sectors [11] - Huiyu Pharmaceutical intends to co-invest in a biomedical venture capital fund with a total initial subscription of 400 million yuan [11] Group 12 - Everbright Bank received notification of a shareholding increase by CITIC Financial Asset Management, raising its stake from 8.00% to 9.00% [12] - Mindray Medical's chairman plans to increase his stake in the company by 200 million yuan within six months [12][13]

Core Viewpoint - The company, Huili Pharmaceutical, announced plans to jointly invest in a new private equity fund focused on the biomedical sector, particularly targeting late-stage clinical projects with clear commercial potential [1] Group 1: Investment Details - Huili Pharmaceutical will collaborate with Hangzhou Xiaochi Private Equity Fund Management Co., Ltd. to establish Chengdu Huili Xiaochi Biomedical Venture Capital Partnership (Limited Partnership) [1] - The initial subscription scale of the private equity fund is set at 400 million yuan, with Huili Pharmaceutical committing 150 million yuan, representing 37.5% of the total initial subscription amount [1]